ATS' DERMAGRAFT FOR DIABETIC ULCERS NEEDS RANDOMIZED POSTMARKET EFFICACY STUDY, PANEL SAYS JAN. 29; SKIN GRAFT APPROVAL SUPPORTED IN 7-2 VOTE
This article was originally published in The Gray Sheet
Advanced Tissue Sciences' Dermagraft premarket approval application to use the bioengineered human skin graft in healing diabetic foot ulcers is approvable with two conditions, FDA's General and Plastic Surgery Devices panel recommended by a 7-2 vote at its Jan. 29 meeting in Gaithersburg, Maryland.
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.